Skyclarys
My Prescription
Payment
Select pharmacy
$35,116.13
Print or send this coupon to your phone
AlbertsonsPowered byAbout Skyclarys
Drug Details
Omaveloxolone, marketed as Skyclarys, is an approved medication for treating Friedreich's ataxia (FA), a rare genetic condition impacting nerves and muscles, primarily in individuals aged 16 and older. This disorder leads to nerve damage, resulting in loss of coordination and unsteady movements. Omaveloxolone is available in capsule form and is taken orally once daily. It functions as an activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which is involved in reducing inflammation to prevent tissue and cell damage. While the exact mechanism by which it alleviates symptoms of Friedreich's ataxia is not fully understood, it is believed to help prevent further nervous system damage. Common side effects may include headache, nausea, stomach pain, and elevated liver enzyme levels. Always consult with a healthcare professional before starting any new medication.
Price history for Skyclarys
90 Capsules, 50MG
Average retail price for Skyclarys
Average SaveHealth price for Skyclarys
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Skyclarys dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 50MG | 90 Capsules | $35,116.13 | $390.18 |
Skyclarys FAQs
Skyclarys is used for the treatment of Friedreich's ataxia, a rare genetic disorder that affects the nervous system and movement.
The cost of Skyclarys can vary depending on factors such as insurance coverage, pharmacy pricing, and location. It is recommended to contact a local pharmacy or healthcare provider for the most accurate and up-to-date pricing information. Additionally, patients may inquire about patient assistance programs or insurance coverage options that could help reduce the cost.
Yes, Skyclarys is considered a specialty drug. Specialty drugs are typically used to treat complex or rare conditions and often require special handling, administration, or monitoring.
Skyclarys (omaveloxolone) is a medication approved for the treatment of Friedreich's ataxia, a rare genetic disorder. Clinical trials have shown that Skyclarys can improve neurological function in patients with this condition. The effectiveness can vary among individuals, and it is important for patients to discuss with their healthcare provider to understand how it may benefit their specific situation.
Yes, Skyclarys (omaveloxolone) is approved by the FDA. It was approved in February 2023 for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.